Bioassay of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) for Neutropenia Treatment in Male Sprague Dawley Rats

Riyona Desvy Pratiwi, Dian Fitria Agustiyanti, Tri Isyani Tungga Dewi, Nina Herlina, Kartika Sari Dewi, Yuliawati Yuliawati, Aminah Aminah, Asrul Muhamad Fuad

Abstract


Background: Recombinant human granulocyte colony stimulating factor (rhG-CSF) is a first line therapy for neutropenia. However, it is less affordable for most patients in developing and poor countries. Therefore, biosimilar products are developed to suppress the cost of treatment, namely with rhG-CSF. This study aimed to explore the establishment of an affordable rhG-CSF that has similar potential to induce neutrophils recovery as the positive control.

Materials and Methods: The rhG-CSF was expressed as inclusion body in Escherichia coli NiCo21(DE3). The inclusion body was then solubilized, refolded, purified and characterized prior to be used in the bioactivity assay. Cyclophosphamide-induced male Sprague Dawley rats were used as animal model and administered with rhG-CSF. Blood sample was collected at several points of time, before and after rhG-CSF treatments. Complete blood count and peripheral blood smear were conducted to investigate the activity of the rhG-CSF on each blood cells type, particularly neutrophil.

Results: Specific activity on neutrophil proliferation was shown after treatments with our rhG-CSF and positive control. Positive control dose 40 mg/kg BW was statistically similar with that of the rhG-CSF dose 80 and 120 mg/kg BW. However, in neutropenic condition, recovery of neutrophil counts could not be achieved within 4 days of treatments. Thus, a longer treatment is needed to observe the activity of the rhG-CSF as an antineutropenia agent.

Conclusion: The rhG-CSF has been proven having specific activity on neutrophil proliferation. However, improvement in the rhG-CSF preparation is still needed and longer administration of the rhG-CSF has to be applied in the future study.

Keywords: rhG-CSF, biosimilar, neutropenia, Sprague Dawley rats


Full Text:

PDF

References


Hill CP, Osslund TD, Eisenberg D. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci. 1993; 90(11): 5167-71, CrossRef.

Seymour JF, Lieschke GJ, Grail D, Quilici C, Hodgson G, Dunn AR. Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival. Blood. 1997; 90(8): 3037-49, CrossRef.

Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100(2): 228-37, CrossRef.

Nurgalieva Z, Liu CC, Du XL. Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer. Med Oncol. 2011; 28(3): 716-25, CrossRef.

Aslam MS, Naveed S, Ahmed A, Abbas Z, Gull I, Athar MA. Side effects of chemotherapy in cancer patients and evaluation of patients opinion about starvation based differential chemotherapy. J Cancer Ther. 2014; 5(8): 817-22, CrossRef.

Lustberg MB. Management of neutropenia in cancer patients. Clin Adv Hematol Oncol. 2012; 10(12): 825-6, article.

Mayordono JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-brea E, Paz-Ares L, Hitt R, Garcia-Rbas I CR. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst. 1995; 87(11): 803-8, CrossRef.

Lieschke G, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood. 1994; 84(6): 1737-46, CrossRef.

Neuman TA, Foote M. The safety profile of filgrastim and pegfilgrastim. In: Graham Molineux, MaryAnn Foote TA, editor. Twenty Years of G-CSF. Berlin: Springer Science & Business Media; 2012. p.395-408, CrossRef.

Advani S, Achreckar S, Thomas D, Krishnankutty B. Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia. Indian J Med Paediatr Oncol. 2010; 31(3): 79-82, CrossRef.

Blackstone EA, Fuhr JP. The economics of biosimilars. Am Heal Drug Benefits. 2013; 6(8): 469-77, article.

Mulcahy AW, Hlavka JP, Case SR. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Perspectives (Montclair). California: Rand Corporation; 2017, article.

Zielinska J, Bialik W. Recent changes on the biopharmaceutical market after the introduction of biosimilar G-CSF products. Oncol Clin Pract. 2016; 12(4): 144-52, article.

Agustiyanti DF, Retnoningrum DS, Rachmawati H, Fuad AM. Overproduction and purification of soluble recombinant human granuocyte colony stimulating factor in Escherichia coli using thioredoxin as fusion. Annales Bogorienses. 2017; 21(1): 1-8, CrossRef.

Pratiwi RD, Fuad AM. Soluble expression of synthetic CSF3syn gene fused with thioredoxin in Escherichia coli BL21(DE3) through autoinduction method and purification. Res Artic Vol Indones J Pharm. 2015; 26(2): 63-70, CrossRef.

Agustiyanti DF, Pratiwi RD, Fuad AM. Pengaruh konsentrasi imidazol pada proses pemurnian protein rekombinan hG-CSF (human granulocyte–colony stimulating factor). Pros Semin Nas Biol 2014 Biol Penelitian, Pengembangan, dan Pembelajarannya Jur Biol Fak Mat dan Ilmu Pengetah Alam Univ Negeri Semarang Maret. 2015; 2015: 240-5.

Pratiwi RD, Fuad AM. Influence of temperature on recombinant granulocyte colony stimulating factor autoinduced production by Escherichia coli BL21(DE3) expression system. Proceding Int Conf Biotechnol 2012 Biotechnol Biodivers to Ind Res Cent Biotechnol Indones Inst Sci. 2013; 2013: 419-28.

Kim CK, Lee CH, Lee SB, Oh JW. Simplified large-scale refolding, purification, and characterization of recombinant human granulocyte-colony stimuating factor in Escherichia coli. PLoS ONE. 2013: 8(11): e80109, CrossRef.

Johnson LA, Malayappan B TN. Formation of cyclophosphamide specific DNA adducts in hematological diseases. Pediatr Blood Cancer. 2012; 58(5): 708-14, CrossRef.

Alyamkina EA, Nikolin VP, Popova NA, Minkevich AM, Kozel AV, Dolgova E V, et al. Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts. Cancer Cell Int. 2015; 15(1): 1-14, CrossRef.

Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA. Side-effects of intravenous cyclophosphamide pulse therapy. Review. 1997; 6(3): 254-7, CrossRef.

McKeon C. Reducing the side effects of chemotherapy. Aust Nurs J. 2012; 19(8): 41, article.

Hattori K, Shimizu K, Takahashi M, Tamura M, Oheda M, Ohsawa N, et al. Quantitative in vivo assay of human granulocyte colony-stimulating factor using cyclophosphamide-induced neutropenic mice. Blood. 1990; 75(6): 1228-33, CrossRef.

Zuluaga F, Jones LM. Protecting indigenous rights in Colombia. Peace Rev. 2006; 18(1): 55-61, CrossRef.

Morley A, Stohlman F. Cyclophosphamide-induced cyclical neutropenia. N Engl J Med. 1970; 282(12): 643-6, CrossRef.

Lim DM. The effect of single administration of rG-CSF on the peripheral neutrophil levels and its dose responsiveness in normal ICR mice and SD rats. J App Pharmacol. 1997; 5: 380-3.

Sari DK, Fuad AM, Yuliawati, Agustiyanti DF, Pratiwi RD. Proses Pembuatan Protein Rekombinan Human Granulocyte-Colony Stimulating Factor (rH-GCSF) Dalam Bentuk Badan Inklusi Menggunakan Bakteri Escherichia coli. Paten No. P00201708906. Bogor: LIPI; 2017.

Laurence AL. Bacharach: Evaluation of Drug Activities. 1st Ed. Massachusetts: Academic Press; 1964, article.

Feng L, Huang Q, Huang Z, Li H, Qi X, Wang Y, et al. Optimized animal model of cyclophosphamide-induced bone marrow suppression. Basic Clin Pharmacol Toxicol. 2016; 119(5): 428-35, CrossRef.

Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2006; 2(3): 271-9, CrossRef.

Giknis MLA, Clifford CB. Clinical Laboratory Parameters for Crl:WI(Han). Wilmington: Charles River; 2008.

Roberts AW. G-CSF: A key regulator of neutrophil production, but that’s not all! Growth Factors. 2005; 23(1): 33-41, CrossRef.

Welte K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med. 1987; 165(4): 941-8, CrossRef.




DOI: https://doi.org/10.21705/mcbs.v4i1.81

Copyright (c) 2020

Indexed by:

                     

                    

                    


Cell and BioPharmaceutical Institute